..in listening to the past 2 CC's and reading on their website, NVAX intimates that their RSV trials are already somewhat derisked. I understand the Maternal trial is a greater leap than the Elderly trial.
Thoughts on likelihood of success of either or both??
I finally bailed out on AMPE after 3 years. Two failed Phase 3 trials and a management team that has over promised but NEVER delivered. It is a mickey mouse team.
If the next Phase 3 trial fails, they go Chapter 11 and stock zeros out. It is now uninvestable, I wouldn't be surprised if their 2 big shareholders - Act & Knoll - bailed out on Bloody Monday.
...he mercifully left the AMPE board after the stock imploded.
Dr's Schwappach in Denver & Dr Ervin in K.C. will return your call or email. Both are current investigators for Ampion. They offer some very good insights.
Bottom line, unless they can get away with an open label extension, you do not want to see THIS management running another double blinded trial. Let a larger Pharma do that.
..otherwise they would have given us the WOMAC #'s. Unreal. How do you go from 26% differentiation between Ampion & Saline in STRUT to that??
One can only hope that this "Gang That Couldn't Shoot Straight" turns Ampion over to another Pharma & management team. The drug works, the management team doesn't.
So to be clear - at 24 weeks you are pain free or mostly pain free?
Based on past correspondences with MM & the likelihood that STRIDE mirrors STRUT, it is highly unlikely that AMPE would accept any offer less than $20-$25/share.
...still over 9 million shares short - 25% of float.